UCB: R&D day a chance to provide update on all programs

By Lisa Kerner

Charlotte, N.C., Sept. 26 - UCB hosted its first research and development day in London to provide an overview of the company's significant projects and promising pipeline.

Officials said the Brussels, Belgium, biopharmaceutical company invests roughly 27% of its sales in R&D.

UCB's R&D efforts are focused on three core therapeutic areas: neurology, immunology and oncology.

The company's research is based in three centers of excellence: Cambridge (UK) for inflammation and Braine-l'Alleud (Belgium) for central nervous system and Slough (UK) for oncology, antibody projects and biological technologies.

As part of its R&D day, UCB disclosed positive phase 2 clinical data on brivaracetam and seletracetam in epilepsy and said it looks for results from a phase 3 study of Keppra XR is the fourth-quarter 2007.

UCB also highlighted its phase 1 clinical development program with UCB 106607 in depression, the start of a phase 2 study early next year of CDP 323 in multiple sclerosis and the novel method of action of the novel compound Cimzia (certolizumab pegol) as a treatment for inflammatory diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.